Delenex Completes its Management Team
(Thomson Reuters ONE) -
Delenex Therapeutics AG /
Delenex Completes its Management Team
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Zürich-Schlieren, Switzerland, Sept 1, 2011.
Delenex Therapeutics AG ("Delenex") announces the appointment of Thomas Jung,
MD, as its Chief Medical Officer.
Thomas Jung brings significant experience in medical research and clinical
development to Delenex. A board certified dermatologist, he has led research
work in immunology at the Novartis Research Institute in Vienna, Austria, then
spent nine years at Novartis in Basel. In January 2008 he took the leadership of
the Ilaris® development team, until its first marketing approval in 2009. Since
then, he was part of the senior leadership team at the Novartis Institute for
Biomedical Research (NIBR), most recently as EU Head of Translational Medicine.
Eric de La Fortelle, CEO of Delenex, said "With the arrival of an experienced
clinician, initially trained in dermatology but with significant clinical
development experience in several other therapeutic areas, notably autoimmunity,
gastroenterology, respiratory, neurosciences and musculoskeletal disorders,
Delenex is able to do full justice to its powerful discovery platform, and
implement the best clinical programs to rapidly bring its major new compounds to
clinical proof of concept. We are happy and proud to welcome him in the
company."
Thomas Hecht, Chairman of the Board, commented: "Delenex is very pleased to
welcome Thomas at its Management Board. Thomas brings all the clinical and
strategic skills to Delenex which are needed to advance our products from
preclinical into and through clinical stages of development. The ability of
Delenex to attract senior leaders from the pharmaceutical industry illustrates
the attractiveness of our value proposition".
About Delenex
Delenex was created in September 2009 as a spin-off from ESBATech (now part of
Alcon, the eye care division of Novartis), and is the exclusive licensee for any
non-ophthalmic uses of ESBATech's products and IPR pre-dating the spin-off.
Delenex' lead compound is DLX105, a small-size, highly tissue-penetrant anti-
TNFalpha antibody that the company intends to develop for topical treatment in
dermatologic indications. Delenex also has several compounds at pre-clinical
stages, among which anti-VEGF, anti-ALK and anti-Abeta antibodies. It is also
using its PENTRA(®) platform to discover new compounds against a selection of
dermatology, CNS and inflammation targets. Delenex' strategy is to discover
highly potent, selective, soluble and stable compounds for local administration
to specific body compartments, such as skin and CNS.
For further information, please contact:
Eric de La Fortelle
Chief Executive Officer
Ph: +41 44 730 5183
Fax: +41 44 730 5181
E-mail: eric.de_la_fortelle(at)delenex.com
Website: www.delenex.com
--- End of Message ---
Delenex Therapeutics AG
Wagistrasse 23 Zürich-Schlieren Switzerland
Press Release:
http://hugin.info/144623/R/1543399/472808.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Delenex Therapeutics AG via Thomson Reuters ONE
[HUG#1543399]
Unternehmensinformation / Kurzprofil:
Datum: 01.09.2011 - 11:12 Uhr
Sprache: Deutsch
News-ID 61428
Anzahl Zeichen: 4012
contact information:
Town:
Zürich-Schlieren
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 205 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Delenex Completes its Management Team"
steht unter der journalistisch-redaktionellen Verantwortung von
Delenex Therapeutics AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
